Consolidated Statements Of Cash Flows (USD $)	3 Months Ended		95 Months Ended
	Aug. 31, 2011	Aug. 31, 2010	Aug. 31, 2011
Cash flows from operating activities
Net loss	$ (1,166,789)	$ (547,950)	$ (16,525,171)
Adjustments to reconcile net loss to net cash used by operating activities:
Amortization / depreciation	838	549	181,687
Loss on disposal furniture & equipment	3,436		3,436
Amortization of original issue discount	2,063		719,265
Extinguishment of debt			(337,342)
Purchased in process research and development			274,399
Stock-based compensation	241,517	262,841	5,961,642
Changes in current assets and liabilities:
Accrued legal settlement
Increase in prepaid expenses	(1,454)	(5,014)	(60,729)
Increase in other assets	(23,815)	1,875	(39,563)
Increase in accounts payable, accrued interest and accrued liabilities	398,955	(17,670)	2,693,859
Net cash used in operating activities	(545,249)	(305,369)	(7,128,517)
Cash flows from investing activities:
Furniture and equipment purchases		(3,480)	(21,083)
Net cash used in investing activities		(3,480)	(21,083)
Cash flows from financing activities:
Capital contributions by president			14,412
Proceeds from notes payable to related parties			705,649
Payments on notes payable to related parties			(165,498)
Proceeds from notes payable issued to individuals			145,000
Payments on notes payable issued to individuals			34,500
Proceeds from convertible notes payable			686,000
Proceeds from the sale of common stock		66,000	4,545,048
Proceeds from Series B preferred stock			2,009,000
Purchase of treasury stock			(436,000)
Proceeds from sale of treasury stock			559,210
Deferred offering costs		(45,800)	(1,029,940)
Proceeds from issuance of stock of AITI acquisition			512,200
Proceeds from issuance of stock of AGTI acquisition			100,000
Proceeds from exercise of warrants			28,350
Net cash provided by financing activities		20,200	7,638,931
Net change in cash	(545,249)	(288,649)	489,331
Cash, beginning of period	1,037,818	700,497	3,238
Cash, end of period	492,569	411,848	492,569
Supplemental disclosure of cash flow information:
Income taxes
Interest	6,102	15,400	30,266
Non-cash investing and financing transactions:
Net assets acquired in exchange for common stock in CytoDyn/Rexray business combination			7,542
Common stock issued to former officer to repay working capital advance			5,000
Common stock issued for convertible debt			662,000
Common stock issued for debt			245,582
Common stock issued for accrued interest payable			20,956
Options to purchase common stock issued for debt			62,341
Original issue discount and intrinsic value of beneficial conversion feature related to debt issued with warrants			719,265
Common stock issued for preferred stock		73,255	167,500
Treasury stock issued for prepaid services			118,291
Common stock issued on payment of accounts payable			49,000
Preferred and common stock subject to rescission	3,000	31,000	4,848,000
Accrued stock incentive and deferred offering costs			1,717,000
Common stock issued for Series B preferred stock			442,984
Series B preferred stock dividends			8,550
Accrued salaries related party contributed as capital		229,500	229,500
Reversal of accrued stock incentive and deferred offering costs			1,717,000
Constructive dividend			$ 6,000,000